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Summary
Objective: Human osteoarthritic (OA) cartilage type-II collagen is preferentially cleaved by the proinﬂammatory cytokine-induced matrix metal-
loproteinases-13 (MMP-13). Interferon-gamma (IFN-g) potently inhibits interleukin-1 (IL-1)-induced MMP-13 expression in healthy chondro-
cytes. Our goal was to study the previously unknown impact of IFN-g on MMP-13 in OA and compare the levels and functional activity of
IFN-g receptor (IFN-gR1) in healthy and OA chondrocytes.
Methods: Chondrocytes were obtained from OA patients and non-arthritic control subjects and treated with IL-1þ or IFN-g. MMP-13 mRNA
and protein expression were measured by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. IFN-gR1 expres-
sion was assessed by ﬂow cytometry, immunoprecipitation and immunohistochemistry with ﬂuorescein-labeled antibody. IFN-gR1 was neu-
tralized with its antibody and signal transducer and activator of transcription 1 (STAT1) phosphorylation analyzed by Western blotting. OA
chondrocytes were also transfected with control and IFN-gR1 expression vectors.
Results: OA chondrocytes displayed a drastically impaired MMP-13 suppression by IFN-g compared to control cells. IFN-gR1 levels were
signiﬁcantly decreased in OA chondrocytes as assessed by ﬂow cytometry, immunoprecipitation and immunohistochemistry. Consequently,
IFN-g-stimulated STAT1 phosphorylation mediated by IFN-gR1 was also considerably reduced in OA patient chondrocytes. IFN-gR1 overex-
pression in OA cells restored MMP-13 suppression by IFN-g.
Conclusions: Ability of IFN-g to suppress IL-1-induced MMP-13 expression is diminished in OA chondrocytes due to decreased IFN-gR1
levels, activity and impaired downstream signal transduction. Therefore, IFN-gR1 modulation and weakened endogenous IFN-g response
may be important mechanisms in OA pathogenesis and cartilage degradation.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Proinﬂammatory cytokines such as interleukin-1 (IL-1) are
believed to be the principal stimuli for driving matrix metal-
loproteinase (MMP)-mediated cartilage degradation in pa-
tients with rheumatoid arthritis (RA) and osteoarthritis
(OA)1. Due to its preferential and efﬁcient cleavage of carti-
lage-speciﬁc type-II collagen, MMP-13 is thought to be the
major enzyme responsible for cartilage collagen degrada-
tion2. Interferon-gamma (IFN-g) is expressed by bacterial
and viral antigen-activated T lymphocytes and natural killer
cells. Contradictory proinﬂammatory and anti-inﬂammatory
roles for IFN-g have been reported, as deﬁciency of IFN-g
or IFN-g receptor (IFN-gR1) reduces3 or enhances4 sus-
ceptibility to collagen-induced arthritis. Despite lack of any
major effect by recombinant IFN-g in a clinical trial on RA*Address correspondence and reprint requests to: Dr M.
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1049patients5, there is a renewed interest in anti-inﬂammatory,
chondroprotective and antiosteoclastogenic effects of
IFN-g6. We have shown that IFN-g potently inhibits IL-1-in-
duced MMP-13 promoter activity and gene expression in
chondrocytes from healthy subjects7. To investigate the sta-
tus of OA cartilage response to IFN-g, the current study
compared previously unknown IFN-g suppression response
of MMP-13 and levels and activity of IFN-gR1 in control and
OA chondrocytes.MethodsCHONDROCYTES AND RT-PCRChondrocytes were released enzymatically from the undamaged cartilage
of the non-weight bearing region of femoral head of four patients (two males,
two females; mean age, 60 years) with hip OA as reported before8, who un-
derwent joint replacement surgery at the Notre-Dame Hospital of CHUM. In-
stitutional ethical committee approved utilization of these tissues. Control
knee chondrocytes from three different subjects (two males, one female;
mean age, 47.3 years) were obtained from Cambrex (Walkerville, MD).
Both groups of chondrocytes at passage 2 showed their typical morphology
and expressed cartilage-speciﬁc collagen II marker as shown below. MMP-
13 and glyceraldehye-3-phosphate dehydrogenase (GAPDH) mRNA levels
were measured by reverse transcription-polymerase chain reaction (RT-
PCR) with MMP-13 speciﬁc primers8 yielding 491 and 226 bp cDNA bands.
1050 R. Ahmad et al.: Impaired response of OA chondrocytes to IFN-gFLOW CYTOMETRY AND IMMUNOHISTOCHEMISTRYOA and control chondrocytes were removed from the culture plates by incu-
bating with 100 mMethylenediaminetetraacetic acid (EDTA) in phosphate-buff-
ered saline (PBS) on ice for 30 min, washed with cold PBS plus 0.2% bovine
serum albumin (BSA) twice and incubated with Phycoerythrin (PE)-conjugated
anti-IFN-gR1 mAb (BD Biosciences, Mississauga ON) or PE-conjugated
mouse immunoglobulin G1 (IgG1) mAb, isotype control for 30 min on ice. After
staining, cells were washed twice with PBS and ﬁxed with cold freshly prepared
2% formaldehyde for 30 min followed by double washingwith PBS prior to anal-
ysis on a Fluorescence-Activated Cell Sorting (FACS) Calibur Flow Cytomer
(BD Biosciences). Control and OA chondrocytes grown in ﬂat-bottomed 96-
well plates were also stained with IFN-gR1 antibody followed by incubation
with Fluorescein isothiocyanate (FITC)-goat anti-mouse secondary antibody.WESTERN BLOTTINGFor Western blotting, 3 106 cells were harvested and incubated for
30 min with lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 30 ml/ml Protease Inhibitor Cocktail Set III-Calbiochem
and 1 mM Na3VO4) and separated by SDS-PAGE. Antibodies against Phos-
pho-STAT1-Tyr-701, total STAT1 (Cell signaling Technology, Beverley, MA),
Collagen II (Chemicon International, Temecula, CA) and beta-actin, (Sigma,
Saint Louis, MO) were used at recommended dilutions. The blots were then
washed and incubated for 2 h with Horse Radish Peroxidase-conjugated
secondary antibody. Immunoreactive bands were developed using an En-
hanced Chemiluminescent substrate (Amersham) and visualized by autora-
diography. For MMP-13, supernatants were collected from the 3 106 cells
cultured in the 9.5 cm2 6-well plates (Costar 3516) and proteins precipitated
with 10% trichloroacetic acid by keeping at 20C for 30 min and then centri-
fuged at 14,000 rpm for 20 min at 4C. The precipitated proteins were dis-
solved in 0.1 M NaOH. Sample loading buffer (100 mM Tris pH 6.8,
200 mM dithiothreitol, 4% SDS, 20% Glycerol, 0.02% Bromophenol blue)
was added, boiled for 5 min and run on SDS-PAGE for separation of pro-
teins. Antibody against MMP-13 (Sigma) was used at 1:500 dilution.IMMUNOPRECIPITATION AND TRANSFECTIONImmunoprecipitation was done as described earlier7. Brieﬂy, 3 106 cells
were lysed on ice for 30 min and lysates centrifuged at 14,000 rpm for 10 min
and supernatants were collected. One milligram of total protein was mixed
with 1 mg/ml monoclonal anti-IFN-gR1 Ab (Chemicon International Inc) or
mouse IgG at 4C for overnight and then protein-A agarose beads were added
and incubated for 3 h at 4C. The precipitates bound to the beads were washed
5 with 1 RIPA buffer and resuspended in 2 SDS loading buffer and then
boiled at 95C for 5 min. Samples were centrifuged and supernatants analyzed
byWestern blotting. Receptor neutralization and transient transfections of Cyto-
megalovirus (CMV) promoter-based pCMV-XL5 and CMV-IFN-gR1 (Origene
SC119876) expression vectors were performed as described earlier7.QUANTIFICATIONThe bands were scanned and quantiﬁed by National Institute of Health Im-
age software by dividing the values of test band by control band (beta-actin,
GAPDH) (arbitrary units) followed by graphic presentation of the mean
values. Differences between mean values of OA patients and controls for
various parameters were tested for statistical signiﬁcance using Student’s t
test. P values of <0.05 were considered signiﬁcant.Results
IFN-g severely suppressed IL-1-induced MMP-13 mRNA
without affecting the constitutive GAPDH mRNA expression
in chondrocytes from control subjects [Fig. 1(A)]. IFN-g alone
did not affect basal MMP-13 expression [Fig. 1(E)]. Although
OA condrocytes appeared to have slightly higher extent of
MMP-13 mRNA induction by IL-1, it was similar after normal-
ization with GAPDH control [Fig. 1(C)]. IFN-g failed to com-
pletely suppress MMP-13 in OA cells [Fig. 1(A)]. MMP-13
protein levels analyzed by Western blotting were compara-
ble (though slightly higher in OA) to those of mRNA
[Fig. 1(B)]. Quantiﬁcation of the bands demonstrated differ-
ential MMP-13 suppression responses of control and OA
chondrocytes to IFN-g [Fig. 1(C) and (D)]. This response
was not due to insufﬁcient IL-1 as doseeresponse showed
maximal MMP-13 mRNA induction with the dose of10 ng/ml used [Fig. 1(F)]. Furthermore, the dose of
300 units/ml IFN-g was sufﬁciently high to effectively sup-
press MMP-13 mRNA and protein expression [Fig. 1(G)].
To investigate the mechanism of differential IFN-g re-
sponse of human OA chondrocytes, we tested the hypothe-
sis that expression of the IFN-gR1 or its activity may be
impaired in OA chondrocytes. IFN-g receptor levels were
measured on chondrocytes from three controls and four
OA patients by ﬂow cytometry. Jurkat cells expressing this
receptor served as positive controls and yielded 92% posi-
tive cells (maximum). Human normal chondrocytes dis-
played higher percentage of (67e69% positive) IFN-gR1
staining [Fig. 2(A) left panels and (B)] compared to severely
reduced percentage (30e34% positive) in OA patient chon-
drocytes [Fig. 2(A), right panels and (B)]. To further examine
the changes in IFN-gR1 expression, immunoprecipitates
from OA patient and control chondrocytes were subjected
to Western blotting. Consistent with the positive control, Ju-
rkat and peripheral blood mononuclear cells (PBMCs), a sin-
gle band of about 90 kDa was reproducibly observed in all
specimens. Diminished expression of IFN-gR1 protein
band in OA chondrocytes was clearly observed by this alter-
native analysis. Based on the ratio of IFN-gR1: b-actin pro-
tein bands, the levels of IFN-gR1 protein expression were
signiﬁcantly different in the two groups [Fig. 2(C) and (D)].
The studied chondrocytesmaintained their phenotype by ex-
pressing consistent levels of chondrocyte-speciﬁc type-II col-
lagen marker as measured by Western blotting including
puriﬁed type-II collagen as positive control [Fig. 2(E)].
Thus, poor response of OA chondrocytes to IFN-g may be
due to diminished expression of IFN-gR1. Indeed, immuno-
histochemistry with IFN-gR1 antibody on two control and
two OA chondrocyte lines indicated decreased IFN-gR1
levels in OA cells [Fig. 2(F)].
STAT1 is a pivotal mediator of IFN-g inhibition of MMP-
137. Further, IFN-g signal transduction takes place primarily
through JAK/STAT pathway9. To further study the mecha-
nism of diminished IFN-g response in OA chondrocytes
and to test whether IFN-g-induced STAT1 phosphorylation
is impaired in OA patients, control and OA chondrocytes
were treated with IFN-g and lysates analyzed by immuno-
blotting with anti-STAT1 antibodies. The total STAT1 levels
remained constant. However, IFN-g-treated chondrocytes
from OA patients displayed signiﬁcantly reduced levels of ty-
rosine-phosphorylated STAT1 (48.50%) [Fig. 3(A) and (B)]
compared to the elevated phosphorylation in control cells.
To investigate whether the decreased pSTAT1 levels are re-
ceptor mediated, we performed receptor neutralization ex-
periments and showed that IFN-gR1 neutralizing antibody
and not IgG completely inhibited IFN-g-stimulated STAT1
phosphorylation [Fig. 3(C)]. IFN-gR1 antibody alone had
no effect [Fig. 3(D)]. We have previously shown that inhibi-
tion of MMP-13 by IFN-g is also mediated by IFN-gR17.
To further explore the role of IFN-gR1 deﬁciency in hypo-
responsiveness of OA chondrocytes, two lines of OA
chondrocytes were transfected with the pCMV-XL5 or
CMV-IFN-gR1 expression vector and then treated with
IL-1 and IFN-g. pCMV-XL5 vector had no effect on IL-1-
induced MMP-13 suppression by IFN-g. CMV-IFN-gR1
overexpression completely (patient 1) or partially (patient
2) restored suppression by IFN-g (Fig. 4).Discussion
We have demonstrated here for the ﬁrst time that com-
pared to controls, human OA chondrocytes have
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Fig. 1. Impaired suppression of IL-1-induced MMP-13 gene expression by IFN-g in human OA chondrocytes. Human chondrocytes from dif-
ferent healthy control subjects (C) or OA patients (P) were treated with vehicle (0.1% BSA), IL-1b (10 ng/ml), IFN-g (300 units/ml) alone or in
combination for 24 h. Cells were harvested for MMP-13 (A, upper panel) and GAPDH (A, lower panel) mRNA analysis by RT-PCR. (B) The
supernatants were used for MMP-13 protein (48 kDa, active enzyme) analysis by Western blotting. (C) Band densities of MMP-13 RT-PCR
products were quantiﬁed in arbitrary units and normalized with GAPDH. The values are the mean and SE. (D) The densities of MMP-13 protein
bands were quantiﬁed and shown as mean values with SE. The mean values of two groups differed signiﬁcantly (P< 0.05). (E) Human chon-
drocytes were treated with vehicle control (BSA), IL-1, IFN-g or both together for 24 h and MMP-13 mRNA and protein analyzed as above.
IFN-g alone does not affect MMP-13 expression. (F) Dose-dependent induction of MMP-13 mRNA and protein by IL-1b providing justiﬁcation
for the use of 10 ng/ml dose. (G) Dose-dependent inhibition of IL-1-induced MMP-13 mRNA and protein by IFN-g in human OA chondrocytes
justifying the 300 Units/ml as the effective dose.
1051Osteoarthritis and Cartilage Vol. 17, No. 8signiﬁcantly reduced repression of MMP-13 induction partly
due to diminished IFN-gR1 levels and resulting impaired
signal transduction through STAT1. We have further shown
directly the expression of IFN-gR1 on chondrocytes.The elevated basal expression of MMP-13mRNA and pro-
tein in OA patients is in agreement with the previous results
which also reconﬁrm the disease-activated state of OA chon-
drocytes and their hypersensitivity to IL-18. Reproducibly
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Fig. 2. Analysis of IFN-gR1 expression on the chondrocytes derived from patients with OA (P) and control (C) subjects. (A) Chondrocyte surface
expression of IFN-gR1 was evaluated by ﬂow cytometry using Jurkat cells (upper panel) as positive controls. The histograms represent the
percentage of cells expressing IFN-gR1 (right panels, white histogram or background of mouse IgG1 negative control gray histogram).
The histogram is representative of three independent experiments for each patient. (B) The mean percentages of chondrocytes expressing
IFN-gR1. A star shows statistically signiﬁcant (P< 0.05) difference between the two groups. (C) The band densities of OA patient and control
IFN-gR1 protein were presented as mean values and SE, which differed signiﬁcantly. (D) Total cell lysates were immunoprecipitated with
anti-IFN-gR1 antibody or control non-immune mouse IgG, resolved by SDS-PAGE and analyzed by Western immunoblotting with
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1053Osteoarthritis and Cartilage Vol. 17, No. 8diminished extent ofMMP-13 suppression by IFN-g inOApa-
tient vs control chondrocytes indicates an inherent defect in
the protective IFN-g response of OA chondrocytes possibly
due to arthritis. A prevailing proinﬂammatory environment in
the joints may be conducive to the observed poor IFN-g
responsiveness. The reported increased susceptibility of
IFN-g- or IFN-gR1-deﬁcient mice to collagen-induced arthri-
tis (a RA-like model) and cartilage and bone loss10 may
also be partly due to defective suppression of MMPs.
By receptor blockade experiments, we have indirectly dem-
onstrated the requirement of IFN-gR1 for repression of MMP-
13 by IFN-g7. However, IFN-g receptor has not been detected
directly in humanoranimal chondrocytes.Hereweshow for the
ﬁrst time that both control and OA chondrocytes express IFN-
gR1. Because the reasons for hypo-effectiveness of IFN-g in
suppressingMMP-13expression inOAchondrocyteswereun-
known, we investigated the hypothesized role of IFN-gR1 by
measuring its levels inboth groupsof chondrocytes.Most inter-
estingly, a consistently diminished expression of IFN-gR1 in
OA chondrocytes from several patients was demonstrated by
multiple approaches of ﬂow cytometry, immunoprecipitation/
Westernblot analysis and immunohistochemistry. Additionally,
constant type-II collagen expression demonstrated thatanti-IFN-gR1 antibody (upper panel). Jurkat cells and PBMCs extracts we
actin analysis (lower panel). (E) For monitoring chondrocyte metabolism a
protein levels in both groups of chondrocytes were determined byWestern
Detection of IFN-gR1 in chondrocytes by using ﬂuorescein-labeled second
48 h. Cells were washed with PBS containing 0.2% BSA and incubated
Chemicon International Cat# MAB1154) for 45 min. Cells were washed tw
(BD Biosciences Cat# 58859) (2 mg/ml). Cells washed and then ﬂuore
C¼Control; P¼OA patients. Light microscope imagechondrocyte phenotype was stable and that the receptor re-
duction was selective and was not due to overall changes in
chondrocytemetabolismas conﬁrmed further byb-actin levels.
Previously, IFN-gR1 expression was found more abundant in
rheumatoid (11/11 patients) thanOA (3/8 patients) synovial tis-
sue11. Depression of IFN-gR1could be a general feature of hu-
man OA tissues that should be studied further. It is noteworthy
that in animal models, IFN-gR1 deﬁciency leads to RA-like
symptoms in multiple joints or an increased susceptibility to
arthritis4,12.
Control and OA chondrocytes displayed signiﬁcantly differ-
ential IFN-g signal transduction response as analyzed by
STAT1 phosphorylation. The reduced STAT1 tyrosine phos-
phorylation in OA chondrocytes strongly correlates with the
aforementioned impaired receptor levels in patient cells and
is indeed mediated by the receptor as shown by the receptor
neutralizationexperiments. Thus IFN-gR1 levels and function-
ality are important in generation of IFN-g responses in chon-
drocytes. Previous reports did not study STAT1 levels in
cartilage but have shown enhanced STAT1 levels in active
RA relative to OA synovial tissue13,14. This may also be true
for cartilage, which is a distinct and essential tissue for weight
bearing, joint ﬂexibility andmobility. The lower IFN-g responsere used as positive controls. Lysates (20 mg) were probed for beta-
nd phenotype, collagen II (upper panel) and beta-actin (lower panel)
blotting using puriﬁed type-II collagen as positive control (lane 1). (F)
ary antibody. Cells were grown in 96-well ﬂat bottom microplates for
with a mouse anti-human IFN-gR1 monoclonal antibody (2 mg/ml;
ice and then probed with FITC-goat anti-mouse secondary antibody
scent images were recorded through ﬂuorescence microscopy.
s of the corresponding regions are also shown.
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1054 R. Ahmad et al.: Impaired response of OA chondrocytes to IFN-gof STAT1 phosphorylation in OA cartilage-derived chondro-
cytes further supports an intrinsic defect. Interferons limit IL-
1-stimulated inﬂammation and tissue destruction by inhibiting
inﬂammatory mediators (cytokines, Cox-2) and MMPs (MMP-
3,MMP-9)15. Such impairment of the defensivemechanism at
multiple levels could lead to enhanced cartilage degradation.
Whether this deﬁciency is a cause or consequence of OA re-
mains to be studied further.
In summary, OA patients exhibit a clear tendency of
impaired IFN-g response and MMP-13 suppression due
to diminished IFN-gR1 levels and subsequent signal
transduction through STAT1. Considering the reported
protective roles of IFN-g in limiting inﬂammation and car-
tilage destruction, such an impaired IFN-g response in pa-
tients may be a pivotal contributing factor for cartilage
degeneration in arthritis and could constitute a therapeutic
target.Conﬂict of interest
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